Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
Eligible age
18+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Women ≥ 18 years of age
- ✓ Histological confirmation of ER+, HER2- breast cancer, newly diagnosed and tissue available for central confirmation of Ki-67 measurement. Subjects are eligible if they have a Ki-67 of ≥10%. Ki-67 will be repeated for patients who have had this done externally.
- ✓ Scheduled for definitive breast surgery
- ✓ Detectable disease as defined by mammography, breast ultrasound of greater than 5mm in size.
- ✓ NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible
- ✓ Post menopausal as defined by:
- ✓ Self-reported last menstrual period greater than 12 months, or
- ✓ Bilateral oophorectomy, or
You may not qualify if…
- ✕ Ki-67 of \<10%
- ✕ Current use of any medicinal mushrooms
- ✕ Patient with locally advanced cancer who will require neoadjuvant therapy or metastatic cancer
- ✕ Currently on systemic chemotherapy
- ✕ Concurrent endocrine therapy (selective estrogen receptor modifiers or aromatase inhibitors)
- ✕ Allergy to mushrooms
- ✕ Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- ✕ Immunocompromised patients
Where it's recruiting
Scottsdale
Source: ClinicalTrials.gov · NCT06450873 · last updated 2026-03-31